Chinook Therapeutics Inc. (NASDAQ:KDNY) finished Thursday with an addition of $0.09 to close at $40.39, an upside of 0.22 percent. An average of 4,228,940 shares of common stock have been traded in the last five days. There was a gain of $0.10 in the past week, and it reached a new high 25 times over the past 12 months. The last 20 days have seen an average of 2,629,690 shares traded, while the 50-day average volume stands at 2,321,130.
KDNY stock has increased by 3.27% in the last month. The company shares reached their 1-month lowest point of $38.86 on 07/21/23. With the stock rallying to its 52-week high on 08/10/23, shares of the company touched a low of $18.34 and a high of $40.47 in 52 weeks. It has reached a new high 14 times so far this year and achieved 54.16% or $14.19 in price. In spite of this, the price is down -0.20% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
KDNY stock investors should be aware that Chinook Therapeutics Inc. (KDNY) stock had its last reported insider trading activity 10 days ago on Aug 01. In this transaction, the insider spent $45,586. Director, Greenman William Mariner, disposed of 1,155 shares at a price of $23.30 on May 30. The insider now owns more than $26,912 worth of shares. Prior to that, President, CEO DOBMEIER ERIC went on to Sale 23,800 shares at $21.58 each on Apr 24. An amount of $513,528 was transacted.
Valuation Metrics
Chinook Therapeutics Inc. (KDNY) stock’s beta is 0.31. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 511.12, the price-to-book (PB) ratio at 6.93.
Financial Health
The quick ratio of Chinook Therapeutics Inc. for the recent quarter was 7.00, and the current ratio was 7.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the recent quarter. Chinook Therapeutics Inc.’s EBITDA margin is -2639.00%. Its gross profit as reported stood at $191.21 million compared to revenue of $6.13 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Chinook Therapeutics Inc.’s return on assets was -37.50%.
Earnings Surprise
For the recent quarter, Chinook Therapeutics Inc. had $170.02 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$66.94 million in the quarter, while revenues were grew 43.76%. Shareholders own equity worth $71.81 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Chinook Therapeutics Inc. (KDNY) price momentum. RSI 9-day as of the close on 10 August was 77.96%, suggesting the stock is Overbought, with historical volatility in this time frame at 13.55%.
As of today, KDNY’s price is $40.33 +0.25% or $0.10 from its 5-day moving average. KDNY is currently trading +2.98% higher than its 20-day SMA and +81.77% higher than its 100-day SMA. However, the stock’s current price level is +66.56% above the SMA50 and +96.83% above the SMA200.
The stochastic %K and %D were 90.91% and 90.76%, respectively, and the average true range (ATR) was 0.27. With the 14-day stochastic at 92.59% and the average true range at 0.36, the RSI (14) stands at 78.49%. The stock has reached 0.16 on the 9-day MACD Oscillator while the 14-day reading was at 0.55.
Analyst Ratings
Wedbush downgraded Chinook Therapeutics Inc. (NASDAQ: KDNY) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as an Outperform. The consensus rating for Chinook Therapeutics Inc. (KDNY) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell KDNY, while 10 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is KDNY’s price target for the next 12 months?
Analysts predict a range of price targets between $40.00 and $47.00, with a median target of $40.00. Taking a look at these predictions, the average price target given by analysts for Chinook Therapeutics Inc. (KDNY) stock is $41.10.
